Stress Urinary Incontinence in Women
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
TBF Genie TissulaireFrance - Mions
1 program1
with treated umbilical vein allograftPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
TBF Genie Tissulairewith treated umbilical vein allograft
Integrated BiosciencesElectroacupuncture group
Clinical Trials (2)
Total enrollment: 454 patients across 2 trials
Treated Umbilical Vein Allograft (UVT) Versus Autologous Fascial Pubovaginal Sling in the Treatment of Female Stress Urinary Incontinence
Start: Nov 2025Est. completion: May 202896 patients
Phase 3Recruiting
Evaluation of Integrated Optimization Schemes for Female Stress Incontinence
Start: May 2014Est. completion: Nov 2017358 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 454 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.